Sat Pharma

SAT Pharma is a German biopharmaceutical company focused on developing next-generation T-cell engagers for the treatment of cancer. Founded by pioneers of the BiTE (Bispecific T-cell Engager) technology, including Peter Kufer and Ralf Bargou, the company aims to overcome the limitations of current immunotherapies through optimized antibody formats. Its lead candidate, SAT-101, is a bispecific antibody targeting BCMA for relapsed or refractory multiple myeloma, designed for enhanced potency and improved safety. The company leverages its proprietary platform to develop a pipeline of innovative therapies for both hematological malignancies and solid tumors. By utilizing deep expertise in antibody engineering, SAT Pharma seeks to provide more effective treatment options for patients with high unmet medical needs.